Mechanism of differences in prolactin levels in patients with schizophrenia after antipsychotics treatment
10.3969/j.issn.1674-8115.2018.07.015
- Author:
Yan-Ge LI
1
Author Information
1. Mental Health Center, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Antipsychotics;
Prolactin;
Schizophrenia
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(7):798-800
- CountryChina
- Language:Chinese
-
Abstract:
Antipsychotics have been the mainstay of schizophrenia treatment, but the frequency of adverse reactions (ARs) related with antipsychotics usage is high. Of all the ARs, hyperprolactinemia is relatively common and the controversy over it remains ongoing, as different patients manifest different prolactin levels and different clinical syndromes. In order to understand this heterogeneity, this review stated the mechanisms underlying the different prolactin levels in schizophrenia patients after antipsychotics treatment, including the ability to block dopamine D2 receptor (DRD2), the influence on blood-brain barrier permeability, varying affinity to DRD2, the inhibition / excitatory effect on DRD2 and genetic polymorphisms.
